Mike,
Where's Ed Thompson?
[break]
MFD:Jumenex for instance, an effective Alzheimer's treatment, has been shown to increase the length of time you retain memories by up to 3x. It's also suspected of helping to prevent you from ever getting Alzheimer's.
Citations, please.
Here I am and here are some recent, somewhat-relevant citations ...
In the fall of 2006, a study was published in the Journal of Child and Adolescent Psychopharmacology communicating the discovery that the active ingredient in Jumenex -- "selegiline" -- was better for kids with ADHD than Ritalin (methylphenidate) is: ********************
Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder.Division of Neurology, Brain and Behaviour Programme, The Hospital for Sick Children, Toronto, Ontario, Canada.
There is evidence suggesting a role for dopamine in attention-deficit/hyperactivity disorder (ADHD). Pharmacological treatments that act on the dopamine system have been successful in reducing ADHD symptoms. However, unlike traditional stimulants (i.e., methylphenidate), selegiline is a monoamine oxidase inhibitor (MAOI) that has been shown to reduce ADHD symptoms without producing undesirable side effects.
In this study using a randomized, double- blind, placebo-controlled, crossover design, cognitive tasks and behavioral rating scales were administered to measure the effectiveness of selegiline in treating different symptoms of ADHD in 11 children aged 6-13.
Results indicate that selegiline may target specific symptoms of ADHD including: sustained attention, the learning of novel information, hyperactivity, and peer interactions.
Because the drug was not associated with negative side effects and did not specifically reduce symptoms of impulsivity, selegiline may be a preferred treatment for individuals who present with the primarily inattentive subtype of ADHD. ******************** Link: http://www.ncbi.nlm.nih.gov/pubmed/16958566
Note the relative absence of side-effects of selegiline (as compared to drugs like Ritalin).
In the spring of 2007, a study was published in the journal, Current Medical Research and Opinion, communicating the discovery that over 1 year of selegiline use (i.e., long-term use) was beneficial to Parkinson's patients ... ******************** Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.Keck/University of Southern California School of Medicine, Los Angeles, CA 90033, USA. marklew@usc.edu
OBJECTIVE: Patients receiving levodopa for Parkinson's disease experience motor fluctuations and immobility ('off' episodes) between doses. This study assessed adjunctive Zelapar (selegiline orally disintegrating tablet (ODT)) for managing off episodes and for long-term safety.
METHODS: This open-label extension evaluated long-term safety, efficacy, and tolerability of adjunctive selegiline ODT 2.5 mg in patients who completed either of two large phase 3 double-blind studies. The study was to end after 12 months but was amended to be open-ended. Investigators could increase levodopa doses and introduce controlled-release formulations of levodopa or dopamine agonists if warranted. Additionally, results of a small randomized trial of open-label selegiline ODT 1.25 mg in comparison to conventional selegiline was added only to the safety analysis. Efficacy variables included changes in daily off time and Patient's Global Impression of Improvement (PGI-I) and Clinical Global Impressions Severity of Disease (CGI-S) ratings. Safety assessments included adverse events and oropharyngeal findings.
RESULTS: This study enrolled 254 patients: 248 from the large phase 3 studies (efficacy analysis) and an additional six from the prior open-label comparison (safety analysis) in order to evaluate a larger population for safety purposes. Mean reduction from baseline in daily off time was 9.4% (1.6 h) for patients previously given selegiline ODT, 6.0% (1.2 h) for those switched from placebo, and 8.1% (1.4 h) overall. PGI-I and CGI-S ratings indicated little or no change from baseline. Treatment-related adverse events occurred in 132 (52%) patients. No severe oral irritations were attributed to selegiline ODT or prompted discontinuation.
CONCLUSIONS: Long-term selegiline ODT 2.5 mg/day was effective, safe, and well tolerated in patients with Parkinson's disease experiencing off episodes during levodopa therapy. ******************** Link:
http://www.ncbi.nlm.nih.gov/pubmed/17407630
Note the dose of 2.5mg per day, which is likely higher than most healthy people would need (for boosting mental performance/longevity). Perhaps Michael Dickey has personal experience with dosing?
In the winter of 2007, a study was published in the journal of HIV Clinical Trials communicating the discovery that transdermal (selegiline patches, absorbed through the skin) selegine, while not helping out on a 6-factor mental performance test, did help HIV patients out on an 8-factor mental performance test: ********************
Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090.Evans SR, Yeh TM, Sacktor N, Clifford DB, Simpson D, Miller EN, Ellis RJ, Valcour V, Marra CM, Millar L, Schifitto G; AIDS Clinical Trials Group and the Neurologic AIDS Research Consortium. Harvard School of Public Health, Boston, Massachusetts, USA.
OBJECTIVE: To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment.
BACKGROUND: HIV infection is associated with increased oxidative stress. In vitro and animal studies have shown that selegiline can reduce oxidative stress levels while enhancing the synthesis of neurotrophic factors. We conducted and reported a 24-week, double-blind, placebo-controlled study with STS in HIV-infected individuals with cognitive impairment (ACTG 5090). We now report the results of the 24-week open-label follow-up.
METHOD: Subjects received either 3 mg/24 h or 6 mg/24 h STS daily. The primary efficacy endpoint was changes in the mean of z scores of six neuropsychological tests (NPZ-6). Additional outcomes included NPZ-8 and NPZ scores by cognitive domain.
Results: 86 subjects were enrolled. There were few severe adverse experiences (n = 13). There was no significant change in NPZ-6 score, whereas significant changes were observed in NPZ-8 score and several cognitive domains.
CONCLUSION: Long-term use of selegiline was safe and well tolerated in this HIV cohort of HIV with cognitive impairment. Cognitive improvement may be delayed in neuroprotective trials, suggesting that trials longer than 6 months may be necessary to assess the efficacy of putative neuroprotective agents.
********************
Link:
http://www.ncbi.nlm.nih.gov/pubmed/18042509
Note that the study went for 2 years (and the dose was moderate-to-high), and they still didn't find any significant side effects of selegiline.
Ed
(Edited by Ed Thompson on 5/09, 10:46am)
|